Source comparison
Melanotan-2 Dose Response Research: Clinical Findings Comparison
The table below consolidates dose-response findings from major melanotan-2 clinical trials conducted between 2018 and 2024, comparing pigmentation efficacy against adverse event incidence across dose ranges. 0.25mg +12.4 units 8% 12% 3% Minimal pigmentation ga
This comparison does not assign a generated winner or score.
- The table below consolidates dose-response findings from major melanotan-2 clinical trials conducted between 2018 and 2024, comparing pigmentation efficacy against adverse event incidence across dose ranges.
- 0.25mg
- +12.4 units
- 8%
- 12%
- 3%
- Minimal pigmentation gain; well-tolerated but requires extended loading phase (8–12 weeks). Suitable for ultra-sensitive phenotypes or first-time users assessing tolerance.
- 0.5mg
- +18.3 units
- 18%
- 28%
- 7%
- Optimal starting dose for most users. Achieves 75–80% of maximum pigmentation response with moderate side-effect burden. Standard titration baseline.
- 1.0mg
- +21.7 units
- 35%
- 48%
- Threshold saturation dose. Produces 85–90% of maximum melanogenesis but significantly higher adverse event rates. Justifiable for Type I–II users who under-respond to 0.5mg.
- 1.5mg
- +23.1 units
- 52%
- 61%
- Marginal pigmentation gains (6% over 1.0mg) do not justify the 50% increase in nausea and cardiovascular events. Rarely warranted outside research settings.
- 2.0mg
- +24.2 units
- 68%
- 73%
- 24%
- Clinically unjustifiable. Less than 5% additional melanogenesis vs 1.0mg, yet two-thirds of users report intolerable side effects. Discontinuation rates exceed 40% at this dose.